Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • China accounts for 66...

    China accounts for 66 percent of India's bulk drug imports in FY'17

    By Ruby Khatun KhatunPublished On 2017-12-20T10:15:17+05:30  |  Updated On 2021-08-17T11:16:59+05:30

    New Delhi: India's bulk drug imports from top five countries stood at Rs 18,372.54 crore in 2016-17 with China accounting for 66 percent, Parliament was informed.


    In a written reply in Lok Sabha, Minister of State, Chemicals and Fertilisers Mansukh L Mandaviya said the other four major countries from where India imports bulk drugs are Germany, the US, Italy, and Singapore.

    India's import of active pharmaceutical ingredients (API) from China stood at Rs 12,254.97 crore in 2016-17, while that from the US was at Rs 820.18 crore.

    API import from Italy was at Rs 701.85 crore during the year under review, while the same from Germany and Singapore was at Rs 485.11 crore and Rs 422.01 crore respectively.

    "It may be mentioned that most of the imports of bulk drugs/API (are) being done in the country because of economic considerations," Mandaviya said.

    As India is a signatory to the WTO and TRIPs agreement, import restrictions have been removed, he added.

    In 2015-16, India's total bulk drug imports from the top five countries were at Rs 21,225.97 crore and it was Rs 19,833.19 crore in 2014-15, the minister added.

    Replying to another query, Mandaviya said the Department of Pharmaceuticals has asked medical device associations, healthcare industry bodies and relevant regulatory agencies to help in categorising medical devices.

    The purpose is to categorise medical devices so as to have different trade margins for various categories for different segments, considering the vast diversity and the logistics required in delivering them to patients, he said.

    "Industry has proposed that the total trade margins for medical devices could be capped to make quality medical devices affordable. Discussions on the issue with industry resulted in the need for categorisation," Mandaviya said, adding there has been no consensus on the issue.
    66 percent accounts active pharmaceutical ingredients agreement API bulk drug imports bulk drugs china Department of Pharmaceuticals Germany India India's bulk drug imports Italy Lok Sabha Mansukh L Mandaviya medical device associations Medical Devices Parliament Singapore TRIPs WTO 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X